Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties

The Plasticity of Oncogene Addiction: Implications for Targeted Therapies Directed to Receptor Tyrosine Kinases

(2015) Vinochani Pillay et al.   NEOPLASIA

Combining molecular targeted therapies

(2011) Xavier Pivot et al.   ANTI-CANCER DRUGS

A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies

(2011) Gabriele Schaefer et al.   CANCER CELL

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung Cancer

(2011) Laura Bonanno et al.   CURRENT DRUG TARGETS

Bispecific digoxigenin-binding antibodies for targeted payload delivery

(2011) S. Metz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy

(2010) Diane Seimetz et al.   CANCER TREATMENT REVIEWS

Safety profile of new anticancer drugs

(2010) Laura Mansi et al.   Expert Opinion On Drug Safety

Bispecific antibodies for cancer therapy

(2010) Patrick Chames et al.   mAbs

Monoclonal antibodies — a proven and rapidly expanding therapeutic modality for human diseases

(2010) Zhiqiang An   Protein & Cell

Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy

(2009) J. Veeken et al.   CURRENT CANCER DRUG TARGETS

Antibodies for Therapeutic Uses and the Evolution of Biotechniques

(2009) P. Nieri et al.   CURRENT MEDICINAL CHEMISTRY

ErbB receptors and signaling pathways in cancer

(2009) Nancy E Hynes et al.   CURRENT OPINION IN CELL BIOLOGY

Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors

(2009) Michalis V Karamouzis et al.   LANCET ONCOLOGY